论文部分内容阅读
目的:探讨谷胱苷肽S转移酶-π(GST-π)和DNA拓扑异构酶I(ITopoII)在涎腺肿瘤组织中的表达及临床意义。方法:采用免疫组化方法检测10例正常涎腺组织、16例涎腺良性肿瘤、27例涎腺恶性肿瘤组织中GST-π、TopoII的表达,分析GST-π、TopoII的表达与涎腺肿瘤临床病理特征。结果:涎腺恶性肿瘤GST-π的阳性率为77.78%,明显高于涎腺良性肿瘤GST-π的阳性率12.50%(P<0.001)。涎腺肿瘤中GST-π表达与TopoII表达之间无明显相关性(P>0.05)。27例涎腺恶性肿瘤中GST-π、TopoII的表达与肿瘤病理类型有关(P<0.05),而与患者的年龄、性别、有无淋巴结转移及临床分期无关。结论:GST-π、TopoII可能与涎腺肿瘤的发生发展相关。检测GST-π、TopoII的表达情况不仅可为涎腺恶性肿瘤化疗用药提供参考,而且可作为涎腺恶性肿瘤判断预后的指标。
Objective: To investigate the expression and clinical significance of glutathione S-transferase-π (GST-π) and DNA topoisomerase I (ITopoII) in salivary gland tumor. Methods: The expressions of GST-π and TopoII in 10 salivary gland tissues, 16 salivary gland benign tumors and 27 salivary gland malignant tumors were detected by immunohistochemistry. The expressions of GST-π, TopoII and salivary gland tumors Clinical and pathological features. Results: The positive rate of GST-π in salivary gland malignant tumors was 77.78%, which was significantly higher than that of GST-π in salivary gland benign tumors (12.50%, P <0.001). There was no significant correlation between GST-πexpression and TopoII expression in salivary gland tumors (P> 0.05). The expression of GST-π and TopoII in 27 salivary gland malignant tumors was correlated with tumor pathological type (P <0.05), but not with age, sex, lymph node metastasis and clinical stage. Conclusion: GST-π, TopoII may be associated with the development of salivary gland tumors. Detection of GST-π, TopoII expression can not only provide a reference for salivary gland malignant tumor chemotherapy drugs, but also can be used as indicators of prognosis of salivary gland malignancy.